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Cystic Fibrosis (CF) is the most common autosomal recessive disease affecting about 1 in 3200 in Caucasians with 
increased morbidity, chronic infections, disability and reduced life expectancy. The mutations causing CF are well 
characterized, but the gene-gene and gene-environment interactions which significantly modify CF disease severity 
are completely unknown. 
We report the pathogenetic mechanisms underlying how a regulatory SNP modifies Cystic Fibrosis (CF). 
Association studies of affected individuals with Cystic Fibrosis identified the causal variant, a regulatory SNP 
rs7910656 on the non-coding region of FAS gene on human chromosome 10q24.1, which includes the binding site 
of many transcription factors especially the NFκB complex, but no molecular alterations were detected by 
conventional approaches. Using a combination of functional in-silico gene expression analysis and computational 
transcription factor binding analysis together with electrophoretic mobility shift and Supershift assays, we have 
identified that an allele of the regulatory SNP disrupts the binding of the master transcription factor NFκB on FAS 
and which likely interferes with normal immune activation and programmed cell death. 
Thus, our work demonstrates for the first time how a regulatory SNP disrupts the binding of a master transcription 
factor NFκB and a key signaling pathway FAS in immune regulation and programmed cell death modifying Cystic 
Fibrosis. 
